Prime Medicines Inc. (PRME), a biotechnology company, on Monday announced the receipt of a Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for PM359, a hematopoietic stem cell therapy for p47phox deficiency chronic granulomatous disease.
Chronic granulomatous disease (CGD) is a rare inherited hematologic disorder characterized by susceptibility to severe infections alongside inflammatory and autoimmune complications. The disease affects the production of functional neutrophils and is diagnosed with a frequency of about one in every 100,000-200,000 individuals in the U.S. alone with the p47phox accounting for 25% of all cases.
PM359 is an investigational autologous hematopoietic stem cell therapy designed to correct the delGT mutation in NCF1, the most prevalent disease-causing mutation in p47phox-deficient CGD. In addition to RMAT designation, PM359 has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA.
The company is currently evaluating PM359 in a multinational, first-in-human Phase 1/2 trial, with initial data providing support for the RMAT designation. The company plans to align with the FDA to advance studies facilitating a future biologics license application (BLA) submission.
If approved, the treatment may be the first approved gene therapy for treating CGD.
PRME is currently trading at $3.43, up 6.35%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.